Haemophilia B
Conditions
Brief summary
This study will collect information on side effects and how well Refixia/REBINYN works during long-term treatment (prophylaxis) in males with haemophilia B. While taking part in this study, participants will receive the same treatment as given to them by their study doctor. All visits at the clinic are done in the same way as the participants are used to. During visits at the clinic, participants might be asked for some relevant tests if considered useful by their study doctor. During the visits, the participants study doctor might ask if the participants had any side effects since their last study visit. The participants will be asked to note down the number of bleeds and the treatment of their bleeds as well as their regular prophylaxis. During the visits to the clinic, the participants will be asked to answer some questionnaires about their quality of life and their ability to be physically active. The participant's participation in the study will last for 4-9 years, depending on when they join the study. Participants are free to leave the study at any time and for any reason. This will not affect their current and future medical care.
Interventions
Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male patients at any age with haemophilia B assigned to N9-GP prophylaxis treatment * Decision to initiate treatment with commercially available N9-GP has been made by the patient(s)/Legally Authorised Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the patient in this study
Exclusion criteria
* Previous participation in this study. Participation is defined as signed informed consent * Known or suspected hypersensitivity to N9-GP or related products * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Clinical suspicion or presence of FIX inhibitor at time of inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Drug Reactions (ADRs) (FIX inhibitors, allergic reactions, and thromboembolic events) | From start of study period (week 0) to end of study period (up to 9 years) | Count of events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Serious Adverse Events (SAEs) | From start of study period (week 0) to up to 9 years | Count of events |
| Number of bleeding episodes during long-term routine use of N9-GP (prophylaxis) as assessed by annualised bleeding rate (ABR) | From start of study period (week 0) to up to 9 years | Count of episodes |
| Number of treatment requiring bleeding episodes during long-term routine use of N9-GP (prophylaxis) as assessed by annualised bleeding rate (ABR) | From start of study period (week 0) to up to 9 years | Number of episodes |
| Haemostatic effect of N9-GP when used for treatment of bleeding episodes | From start of study period (week 0) to up to 9 years | Count of bleeding episodes. Haemostatic effect is assessed as success/failure based on a four-point scale for haemostatic response (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure |
| Haemostatic response of N9-GP when used in perioperative management | From start of study period (week 0) to end of study period (up to 9 years) | Count of bleeding episodes. Haemostatic response is assessed as success/failure based on a four-point scale for haemostatic response (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure |
Countries
Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, Germany, Greece, Norway, Portugal, Switzerland, United Kingdom
Contacts
STUDY_DIRECTORClinical Reporting Anchor and Disclosure (1452)
Novo Nordisk A/S
Outcome results
None listed